Inherited retinal diseases (IRDs) are a diverse group of genetic conditions that progressively impair vision, often leading to blindness. Among these, Cone-Rod Dystrophy (CRD) is a particularly challenging condition where the cone photoreceptors, responsible for central vision and color perception, are primarily affected, followed by the rod photoreceptors that handle night and peripheral vision. This progressive degeneration can significantly impact daily life, making activities like reading and driving increasingly difficult.

A recent nationwide study from Portugal, published in Clinical & Experimental Ophthalmology in 2026, sheds new light on retinal dystrophies linked to the RPGR gene. Titled "Clinical and Genetic Landscape of RPGR-Associated Retinal Dystrophies in Portugal: Insights From the Nationwide IRD-PT Registry," this research offers crucial insights into the clinical presentation and genetic underpinnings of these conditions, which are among the most severe IRDs.

Understanding RPGR-Associated Retinal Dystrophies

The RPGR gene (Retinitis Pigmentosa GTPase Regulator) is located on the X chromosome, meaning that mutations in this gene primarily affect males, though female carriers can also experience symptoms. These mutations are a leading cause of X-linked retinitis pigmentosa (XLRP), a severe form of IRD, and are also associated with Cone-Rod Dystrophy. The RPGR protein plays a vital role in the development and function of photoreceptor cells, and its absence or malfunction leads to their gradual degeneration and vision loss.

Key Findings from the Portuguese Study

This comprehensive study analyzed 103 individuals from 40 families in Portugal, providing the first nationwide overview of RPGR-associated disease in the region. The findings revealed several important characteristics:

  • Predominant Phenotypes in Males: The majority of affected males (82.8%) presented with X-linked retinitis pigmentosa (XLRP), typically showing symptoms in childhood or adolescence (mean onset 13.1 years). A smaller proportion of males (17.2%) developed cone/cone-rod dystrophy, which tended to manifest later in life.
  • Visual Acuity: The visual acuity in males was comparable to international cohorts, and, as expected, declined with age.
  • Variability in Female Carriers: Female carriers of RPGR mutations showed a wide range of clinical presentations. While many maintained preserved central vision, fundus autofluorescence (FAF) imaging revealed a spectrum from nearly normal retinal health to patterns resembling the more severe disease seen in males. FAF is a non-invasive imaging technique that visualizes metabolic activity in the retinal pigment epithelium and is valuable for diagnosing and monitoring IRDs. The severity observed on FAF strongly correlated with visual acuity, indicating its clinical utility in assessing female heterozygotes. Notably, interocular asymmetry (differences between the eyes) was observed in over 20% of females.
  • Genetic Landscape: The study identified 29 distinct RPGR variants, 11 of which were novel. Truncating variants, particularly within the ORF15 region of the gene, were the most common, accounting for 63% of genetically confirmed cases. The ORF15 region is known as a mutational hotspot for RPGR-associated conditions.
  • Genotype-Phenotype Correlations: The research reinforced established patterns, showing that variants located distally (further along the gene) in RPGR were associated with cone-dominant disease, while proximal variants (closer to the beginning of the gene) were linked to rod-cone dystrophy.

Implications for Treatment and Future Directions

The detailed clinical and genetic characterization provided by this study is crucial for improving the diagnosis and counseling of individuals and families affected by RPGR-associated retinal dystrophies. By expanding the known mutational landscape, the research aids in more precise genetic testing and understanding of disease progression.

Furthermore, these findings have significant implications for the development and application of gene-based therapies. Several gene therapy approaches for RPGR-associated XLRP are currently in clinical trials, showing promise in restoring retinal function. The study's emphasis on harmonized phenotyping and full-length RPGR sequencing will help identify suitable candidates for these emerging treatments and optimize trial design. The ability to accurately characterize the disease, especially in female carriers using tools like FAF, is vital for monitoring treatment efficacy and understanding long-term outcomes.

A Forward Look

This Portuguese study represents a significant step forward in our understanding of RPGR-associated retinal dystrophies. It underscores the importance of comprehensive national registries and advanced imaging techniques in unraveling the complexities of IRDs. As gene therapies continue to advance, such detailed population-level data will be instrumental in translating scientific breakthroughs into effective treatments that can preserve and restore vision for patients worldwide. The ongoing research into RPGR gene therapy offers hope for individuals living with these challenging conditions, moving us closer to a future where vision loss from IRDs can be effectively managed or even prevented.